OncoMatch/Clinical Trials/NCT07011004
A Study of Natural Killer Cells in Combination With Atezolizumab in People With Acute Myelogenous Leukemia
Is NCT07011004 recruiting? Yes, currently enrolling (Jun 2026). This Phase 1 trial studies multiple treatments including Cytokine Induced Memory-Like Natural Killer Cells and Atezolizumb for acute myeloid leukemia refractory.
Treatment: Cytokine Induced Memory-Like Natural Killer Cells · Atezolizumb · CIML-NK cell therapy — The researchers are doing this study is to find the highest dose of cytokine-induced memory-like (CIML) natural killer (NK) cells in combination with the drug atezolizumab that causes few or mild side effects in people with relapsed/refractory acute myelogenous leukemia (AML). The researchers will also look at whether the treatment combination works against participants' cancer.
Check if I qualifyExtracted eligibility criteria
Treatments studied
Other
Cancer type
Acute Myeloid Leukemia
Biomarker criteria
Allowed: FLT3 ITD mutation
Patients with FLT3-ITD or -TKD mutations must have received at least one commercially available inhibitor of FLT3.
Allowed: FLT3 TKD mutation
Patients with FLT3-ITD or -TKD mutations must have received at least one commercially available inhibitor of FLT3.
Allowed: NPM1 mutation
Patients with NPM1 mutation or rearrangements of MLL must be refractory to revumenib.
Allowed: KMT2A (MLL) rearrangement
Patients with NPM1 mutation or rearrangements of MLL must be refractory to revumenib.
Allowed: IDH1 mutation
Patients with mutations in IDH1 or IDH2 must be refractory to at least one commercially available inhibitor of IDH1 or IDH2, respectively.
Allowed: IDH2 mutation
Patients with mutations in IDH1 or IDH2 must be refractory to at least one commercially available inhibitor of IDH1 or IDH2, respectively.
Demographics
Prior therapy
Must have received: combination chemotherapy (daunorubicin, anthracycline) — induction
Refractory to at least two attempts at prior induction therapy. An attempt is defined as either a single cycle of combination chemotherapy such as daunorubicin/anthracycline
Must have received: hypomethylating agent with venetoclax (hypomethylating agent, venetoclax) — induction
A single monthly cycle of a hypomethylating agent with venetoclax
Must have received: FLT3 inhibitor
Patients with FLT3-ITD or -TKD mutations must have received at least one commercially available inhibitor of FLT3.
Must have received: revumenib (revumenib)
Patients with NPM1 mutation or rearrangements of MLL must be refractory to revumenib.
Must have received: IDH1 inhibitor
Patients with mutations in IDH1 or IDH2 must be refractory to at least one commercially available inhibitor of IDH1 or IDH2, respectively.
Must have received: IDH2 inhibitor
Patients with mutations in IDH1 or IDH2 must be refractory to at least one commercially available inhibitor of IDH1 or IDH2, respectively.
Cannot have received: allogeneic hematopoietic cell transplantation
Prior allogeneic hematopoietic cell transplantation
Lab requirements
Kidney function
estimated or measured creatinine clearance > 50 ml/min
Liver function
serum bilirubin ≤ 5 mg/dl; ast and alt ≤ 2.5x uln unless thought to be disease related
Cardiac function
systolic lv ejection fraction ≥50% at rest and absence of new york heart association stage iii or iv congestive heart failure
Structured fields extracted by AI. May contain errors — verify against the official protocol.
US trial sites
- Memorial Sloan Kettering at Basking Ridge (Limited Protocol Activities) · Basking Ridge, New Jersey
- Memorial Sloan Kettering Monmouth (Limited protocol activities) · Middletown, New Jersey
- Memorial Sloan Kettering Bergen (Limited Protocol Activities) · Montvale, New Jersey
- Memorial Sloan Kettering Suffolk - Commack (Limited protocol activities) · Commack, New York
- Memorial Sloan Kettering West Harrison (Limited Protocol Activities) · Harrison, New York
Showing up to 5 US sites.
See all sites on ClinicalTrials.gov →Frequently asked questions
Is NCT07011004 currently recruiting?
Yes, this trial is currently recruiting patients.
Are there prior therapy exclusions?
Yes. Prior allogeneic hematopoietic cell transplantation disqualifies patients from enrollment.
Is there an age limit?
Yes. Patients must be 70 years or younger.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualifyRelated pages